X-ray structure breakthroughs in the GPCR transmembrane region.
G-protein-coupled receptor (GPCR) proteins [Lundstrom KH, Chiu ML, editors. G protein-coupled receptors in drug discovery. CRC Press; 2006] are the single largest drug target, representing 25-50% of marketed drugs [Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there? Nat Rev Drug Discov 2006;5(12):993-6; Parrill AL. Crystal structures of a second G protein-coupled receptor: triumphs and implications. ChemMedChem 2008;3:1021-3]. While there are six subclasses of GPCR proteins, the hallmark of all GPCR proteins is the transmembrane-spanning region. The general architecture of this transmembrane (TM) region has been known for some time to contain seven alpha-helices. From a drug discovery and design perspective, structural information of the GPCRs has been sought as a tool for structure-based drug design. The advances in the past decade of technologies for structure-based design have proven to be useful in a number of areas. Invoking these approaches for GPCR targets has remained challenging. Until recently, the most closely related structures available for GPCR modeling have been those of bovine rhodopsin. While a representative of class A GPCRs, bovine rhodopsin is not a ligand-activated GPCR and is fairly distant in sequence homology to other class A GPCRs. Thus, there is a variable degree of uncertainty in the use of the rhodopsin X-ray structure as a template for homology modeling of other GPCR targets. Recent publications of X-ray structures of class A GPCRs now offer the opportunity to better understand the molecular mechanism of action at the atomic level, to deploy X-ray structures directly for their use in structure-based design, and to provide more promising templates for many other ligand-mediated GPCRs. We summarize herein some of the recent findings in this area and provide an initial perspective of the emerging opportunities, possible limitations, and remaining questions. Other aspects of the recent X-ray structures are described by Weis and Kobilka [Weis WI, Kobilka BK. Structural insights into G-protein-coupled receptor activation. Curr Opin Struct Biol 2008;18:734-40] and Mustafi and Palczewski [Mustafi D, Palczewski K. Topology of class A G protein-coupled receptors: insights gained from crystal structures of rhodopsins, adrenergic and adenosine receptors. Mol Pharmacol 2009;75:1-12].
Topiol
Sid
S
Department of Computational Chemistry, Lundbeck Research USA, Inc., 215 College Road, Paramus, NJ 07652, USA.
Sabio
Michael
M
D000818:Animals; D002462:Cell Membrane / Q000648:ultrastructure; D006801:Humans; D008958:Models, Molecular; D008968:Molecular Conformation; D010869:Pindolol / Q000031:analogs & derivatives / Q000737:chemistry; D011412:Propanolamines / Q000737:chemistry; D011487:Protein Conformation; D043705:Receptor, Adenosine A2A / Q000737:chemistry / Q000502:physiology; D018343:Receptors, Adrenergic, beta-2 / Q000737:chemistry / Q000502:physiology; D043562:Receptors, G-Protein-Coupled / Q000737:chemistry*; D012172:Retinaldehyde / Q000737:chemistry; D012243:Rhodopsin / Q000737:chemistry / Q000502:physiology; D014961:X-Ray Diffraction
D011412:Propanolamines; D043705:Receptor, Adenosine A2A; D018343:Receptors, Adrenergic, beta-2; D043562:Receptors, G-Protein-Coupled; C014382:carazolol; C047975:cyanopindolol; D012243:Rhodopsin; D010869:Pindolol; D012172:Retinaldehyde